Our results showed that upregulated m6A peaks in the CYP-treated NRCMs were significantly related to the cAMP signaling pathway, adrenergic signaling in cardiomyocytes, calcium signaling pathway, GnRH signaling pathway and other dysregulation pathways in cancer (Figure 4F). Here, GNRH1 is linked to cancer.